Expert Interview
Delving into BiolineRx's APHEXDA (Motixafortide)(BL-8040): Stem Cell Mobilization in Multiple Myeloma with a PDUFA Date of September 9, 2023
Ticker(s): BLRXInstitution: UT MD Anderson Cancer Center
- Professor in the department of stem cell transplantation and cellular therapy at UT MD Anderson Cancer Center.
- Manages 100 patients with Multiple Myeloma
- Clinical and research work focuses on improving the outcomes of stem cell transplantation and cellular therapy for patients with multiple myeloma and related disorders.
- Has authored or co-authored more than 270 articles in peer-reviewed medical journals, and serves in leadership positions at various institutional and extramural committees
Can you tell us what makes the mechanism of action behind APHEXDA unique and its role as a CXCR4 antagonist?
Judging from your experience, how does APHEXDA stand out in comparison to the current SCM treatments for MM?
Added By: catalin_adminWhat are the most pressing challenges in SCM for MM, and how might APHEXDA address these issues?
With the introduction of APHEXDA, how do you foresee the shift in the therapeutic landscape of SCM in MM?
Based on the data you've encountered, are there any specific safety signals or concerns associated with APHEXDA?
Added By: catalin_adminConsidering the rapid advancements in MM treatments, where does APHEXDA fit, and what could be its long-term implications in the SCM domain?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
